CSP Research Priority Announcement Post Traumatic Stress Disorder (PTSD) Research

August 1, 1997

Office of Research and Development

VA Cooperative Studies Program (CSP)

Research Priority Announcement

Post Traumatic Stress Disorder (PTSD) Research

The VA Cooperative Studies Program has identified the following PTSD research content areas as priority for the conduct of multi-site, randomized clinical trials:

- "Phase II" studies to assess evidence of a specific effect of particular treatment strategies on PTSD; studies designed to determine threshold effects of "doses" of psychosocial interventions/psychotropic medications; and other innovative treatment intervention approaches.
- Studies of specific treatments aimed at "special subpopulations" of patients with PTSD (e.g., women veterans, Gulf War veterans, so called "Atomic" veterans and patients identified through a primary care intake process or through identification of another physical illness).
- Studies of treatments aimed primarily at comorbid disorders, especially prevalent in PTSD patients, that require specialized management.
- Studies of treatments effects on "preclinical" markers which might be used as screens for treatment strategies especially those that merit full-scale testing.

Application Process.

1. Interested investigators should contact Joe Gough, MA, Cooperative Studies Program Analyst, to request a copy of Instructions for Submission of a CSP Planning Request. CSP Planning Requests may be submitted at any time.

2. Submit five copies of the CSP Planning Request and curriculum vitae to: VA Headquarters, Cooperative Studies Program (124D), 810 Vermont Avenue, NW, Washington, DC 20420. All CSP Planning Requests will be reviewed by ad hoc

experts in the field of research proposed. Notification of the Planning Request review disposition will be provided in approximately one month.

3. Investigators with an approved CSP Planning Request will be assigned by VA CSP Headquarters to one of the four VA Cooperative Studies Coordinating Centers for technical assistance and guidance in development of a full study protocol.

John R. Feussner, M.D.
Chief Research and Development Officer